Schedule 13D ownership disclosure

Bicara Therapeutics Inc

Common Stock, par value $0.0001 per share · CUSIP: 055477103

Event date: 2026-02-26

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • RA Capital Management, L.P.Reported CIK 0001346824

    Shares: 7,279,739.00 · Class: 11.5%

  • Peter KolchinskyReported CIK 0001384859

    Shares: 7,279,739.00 · Class: 11.5%

  • Rajeev ShahReported CIK 0001619841

    Shares: 7,279,739.00 · Class: 11.5%

  • RA Capital Healthcare Fund, L.P.Reported CIK 0001315082

    Shares: 4,603,418.00 · Class: 7.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001346824-26-000066
Form type
SCHEDULE 13D/A
Filer
Bicara Therapeutics Inc.
CIK
CIK 2023658
Filed
Mar 02, 2026
Reporting period
Feb 26, 2026
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub